Skip to content

Utility of 3D Navigation to Reduce Ionizing Radiation in Common Flutter Ablation. Study of Personnel and Patient Dosimetry

Utility of 3D Navigation to Reduce Ionizing Radiation in Common Flutter Ablation. Study of Personnel and Patient Dosimetry

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03946280
Acronym
DOSIMETRY-AFL
Enrollment
50
Registered
2019-05-10
Start date
2018-11-01
Completion date
2020-11-01
Last updated
2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Auricular Flutter, Radiation Exposure

Keywords

ALARA, radiation exposure, Flutter ablation

Brief summary

Common Flutter ablation technique use low X-ray based three-dimension (3D) navigation for catheter tracking, have become a popular implementation to treat patient's underlying arrhythmia. Compared with fluoroscopy, the gold standard X-ray based method, this recent technique provides the required anatomical information and reduce risk associated with ionizing radiation exposure. Besides Practical Guidelines as low as reasonably achievable (ALARA) to minimize and normalize radiation exposure had been published so far. The risk of developing acute radiation associated injuries still remains high. In the present study we will compare two groups of patients undergoing into cavotricuspid isthmus (CTI) ablation using either the 3D navigation (Ensite NavX system) (n = 25) or conventional fluoroscopy (n = 25). Further developing the 3D navigation technique will help to increase safety during the treatment, for both patients and the personnel and increase the success rate during the electrophysiological (EP) interventional procedures.

Interventions

PROCEDUREconventional X-ray based Fluoroscopy

catheter tracking via conventional X-ray based Fluoroscopy

PROCEDURElow X-ray 3D navigation technique

catheter tracking via low X-ray 3D navigation technique

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Randomized study, patients are allocated to 1 of the 2 groups

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Sick adult patients with Atrial Flutter arrythmia * patients able to consent. * patients scheduled to receive cavotricuspid isthmus ablation treatment

Exclusion criteria

* patients who do not meet inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Number of Participantsthrough study completion, an average of 2 yeartwo groups and 25 patiens within each group
ageat the moment the patient was recruited for the studyage in years of every patient in the study
Electrophysiology procedure time (EP time)at the moment of the interventiontime the intervention last in minutes
Radiofrecuency ablation timeat the moment of the interventiontime radiofrecuency are applied within the EP time in minutes/ seconds
Total Fluoroscopy timeat the moment of the interventiontime the patiens receive x ray radiation along the intervention in minutes/ seconds
Time without fluoroscopyat the moment of the interventiontime the patiens do not receive any x ray radiation along the intervention in minutes/ seconds
Dose area productat the moment of the interventionGlobal Radiation dose emited by the x-ray tube in mgcm2
Radiation dose TLD in patient (5 TLD)at the moment of the interventionfive thermoluminescent dosimeters are placed on the body of the patient in mgcm2
Radiation dose TLD in operator (3 TLD)at the moment of the interventionthree thermoluminescent dosimeters are placed on the body of the patient in mgcm2
readmissionwithin 12 months following the EPtimes the patient is readmitted in the hospital

Countries

Belgium

Contacts

Primary ContactChristophe Scavée, PhD, MD
christophe.scavee@uclouvain.be+3227642808
Backup ContactYovan Sanchez Ruiz, PhD
Yovan.sanchezruiz@student.uclouvain.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026